Jefferies Financial Group Inc. Purchases 12,451 Shares of Elevance Health, Inc. $ELV

Jefferies Financial Group Inc. boosted its position in Elevance Health, Inc. (NYSE:ELV) by 1,892.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,109 shares of the company’s stock after buying an additional 12,451 shares during the quarter. Jefferies Financial Group Inc.’s holdings in Elevance Health were worth $4,236,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of ELV. Vanguard Group Inc. lifted its position in Elevance Health by 0.6% during the 3rd quarter. Vanguard Group Inc. now owns 22,998,645 shares of the company’s stock worth $7,431,322,000 after acquiring an additional 141,747 shares during the last quarter. Sanders Capital LLC boosted its holdings in Elevance Health by 24.7% during the second quarter. Sanders Capital LLC now owns 5,825,208 shares of the company’s stock valued at $2,265,773,000 after acquiring an additional 1,152,440 shares during the period. Artisan Partners Limited Partnership grew its position in shares of Elevance Health by 24.5% in the third quarter. Artisan Partners Limited Partnership now owns 4,576,805 shares of the company’s stock valued at $1,478,857,000 after purchasing an additional 901,626 shares during the last quarter. First Eagle Investment Management LLC grew its position in shares of Elevance Health by 25.0% in the third quarter. First Eagle Investment Management LLC now owns 3,998,603 shares of the company’s stock valued at $1,292,029,000 after purchasing an additional 798,457 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Elevance Health in the second quarter worth about $1,148,379,000. Institutional investors own 89.24% of the company’s stock.

Elevance Health Stock Down 3.1%

ELV stock opened at $280.80 on Tuesday. Elevance Health, Inc. has a twelve month low of $273.71 and a twelve month high of $458.75. The company has a market cap of $61.98 billion, a PE ratio of 11.18, a price-to-earnings-growth ratio of 1.60 and a beta of 0.51. The business’s 50-day simple moving average is $343.29 and its 200 day simple moving average is $335.14. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.70.

Elevance Health (NYSE:ELV) last posted its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, beating the consensus estimate of $3.10 by $0.23. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The firm had revenue of $49.31 billion during the quarter, compared to analysts’ expectations of $49.52 billion. During the same quarter in the prior year, the firm posted $3.84 EPS. The company’s revenue for the quarter was up 9.6% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, research analysts anticipate that Elevance Health, Inc. will post 33.96 earnings per share for the current year.

Elevance Health Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be paid a $1.72 dividend. The ex-dividend date is Tuesday, March 10th. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.5%. Elevance Health’s dividend payout ratio is currently 27.23%.

Analyst Ratings Changes

ELV has been the subject of several research analyst reports. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $332.00 price objective on shares of Elevance Health in a research report on Thursday, January 29th. Morgan Stanley lowered their target price on Elevance Health from $359.00 to $352.00 and set an “equal weight” rating on the stock in a report on Wednesday, December 17th. Leerink Partners lifted their price target on Elevance Health from $350.00 to $357.00 and gave the stock a “market perform” rating in a research report on Thursday, January 29th. Wall Street Zen cut Elevance Health from a “buy” rating to a “hold” rating in a research report on Sunday, February 8th. Finally, Robert W. Baird increased their price objective on Elevance Health from $297.00 to $340.00 and gave the company a “neutral” rating in a research report on Thursday, December 11th. Twelve investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $390.55.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.